IDrugs 2004-01-01

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

R Todd Reilly

Index: IDrugs 7(1) , 64-9, (2004)

Full Text: HTML

Abstract

BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.

Related Compounds

  • Coenzyme M

Related Articles:

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.

2011-02-01

[Cancer Chemother. Pharmacol. 67(2) , 381-91, (2011)]

Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).

2008-10-01

[J. Thorac. Oncol. 3(10) , 1159-65, (2008)]

New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.

2003-07-01

[Cancer Chemother. Pharmacol. 52 Suppl 1 , S3-15, (2003)]

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.

2010-04-01

[Cancer Chemother. Pharmacol. 65(5) , 941-51, (2010)]

Vibrational spectroscopic studies of mesna and dimesna.

2003-06-01

[Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 59(8) , 1791-8, (2003)]

More Articles...